InterCure Ltd. (NASDAQ: INCR) reported preliminary full‑year 2025 revenue of NIS 265 million, an 11% increase from the NIS 239 million recorded in 2024. The company’s top‑line growth was driven largely by a 20% rise in the second half of the year, when it generated NIS 135 million in revenue, marking the first significant sales in the German market.
The company’s cash balance stood at NIS 43 million as of December 31 2025, while it launched more than 70 new GMP‑certified SKUs during the year. InterCure’s operations at the Nir Oz facility resumed production, importation, and sales after the October 7 attack, restoring a key source of revenue and reinforcing its vertically integrated, pharmaceutical‑grade platform.
Strategic moves continued to shape the business. InterCure entered a share purchase agreement to acquire Botanico Ltd., with expected revenues exceeding NIS 30 million in the second half of 2026 upon closing. In November 2025, the company acquired a 28% stake in Cannasoul R&D Ltd., with a path to increase holdings to 51% within two years. These investments are positioned to strengthen the company’s global reach and research capabilities.
Management highlighted the German market milestone and the company’s broader expansion strategy. “2025 marked a year of disciplined execution and renewed growth for InterCure. We delivered meaningful acceleration in the second half of the year with nearly 20% revenue growth and achieved our twelfth consecutive half‑year of positive Adjusted EBITDA,” said CEO Alexander Rabinovich. He added, “The anticipated commencement of operations under the Botanico transaction and our strategic collaboration with Cannasoul are expected to further strengthen our pharmaceutical platform and global positioning.”
Headwinds remain, including a NIS 251 million war‑related damages claim and an NIS 81 million compensation advance, as well as legal uncertainty surrounding the restructuring proceedings at Bazelet. Nevertheless, the company’s entry into Germany and its focus on evolving cannabis regulations in Europe and the U.S. provide tailwinds that support continued growth and operational resilience.
Overall, InterCure’s preliminary results demonstrate sustained profitability, with positive Adjusted EBITDA in both halves of the year and a clear trajectory of revenue acceleration. The company’s strategic acquisitions, expanded product portfolio, and renewed market presence position it for continued expansion in the pharmaceutical‑grade cannabis sector.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.